420 with CNW — Kentucky’s First Lottery Selects 26 Businesses to Receive Medical Marijuana Licenses

Kentucky is making significant progress toward introducing medical cannabis as an option for healthcare in the state. Recently, 26 businesses were chosen to cultivate and process medical cannabis, which will soon be available for sale across Kentucky. The businesses earned their licenses through a random lottery held at the Kentucky Lottery office in Louisville.

Governor Andy Beshear expressed enthusiasm about the milestone, highlighting that all medical marijuana activities—from cultivation and processing to testing and dispensing—will occur within Kentucky. Further, he stated that the lottery was a step closer to providing safe and affordable access to medical marijuana for Kentuckians dealing with severe health conditions.

In his remarks, Beshear shared that the start date for patient access could be as soon as January 1 or shortly thereafter, as dispensaries and other necessary facilities begin operations. “A new day is approaching in Kentucky,” he noted, with safe, regulated medical cannabis soon available to support qualifying patients in managing their health conditions.

The Office of Medical Cannabis (OMC) executive director, Sam Flynn, shared that the state received 4,998 applications for business licenses related to medical cannabis, with 918 applicants aiming for processing and cultivation roles. Approximately 84% of these applications were approved for participation in the lottery.

Flynn further explained that the lottery approach was based on examining best practices in other states with established medical marijuana programs. “We prioritized creating a transparent and fair process from the start,” he added.

The lottery winners have fifteen days to pay their processing or cultivation license fees or risk losing the license. Once fees are paid, the OMC will officially grant the licenses, allowing businesses to start operations.

Under the program, cultivators will be required to grow cannabis in secure, locked facilities. They will then sell the harvested cannabis to processors, who will develop various medical cannabis products from the raw material.

A date for a separate lottery to award 48 dispensary licenses is expected to be announced on Thursday.

In September, the state took an initial step by awarding its first marijuana business license to a testing laboratory in Nicholasville. The facility is expected to examine products for safety and quality before they reach patients.

Eligible conditions include any form or stage of cancer; severe, chronic, or incapacitating pain; epilepsy or other chronic seizure disorders; post-traumatic stress disorder (PTSD); multiple sclerosis or associated muscle spasms; and chronic nausea or vomiting that resists conventional treatments.

The entire cannabis industry, including firms like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), will be hoping that the roll out of the medical marijuana program in Kentucky goes without a hitch and gives patients who need those products a chance to access them legally.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Officials Question Voter Signatures in Bid to Thwart Medical Marijuana Measure

Nebraska’s top election official and the state’s chief prosecutor are raising concerns about the validity of most signatures gathered for two medical marijuana petitions set to appear on the ballot this November. Mike Hilgers, Nebraska’s attorney general, who filed a legal motion on behalf of Bob Evnen, secretary of state, stated that inquiries are still being conducted to determine whether the 49,000-plus confirmed signatures on these petitions are authentic.

With early voting already underway on whether to legalize or regulate medical cannabis, Evnen and Hilger are urging the court to verify the total number of valid signatures and potentially nullify the election results if enough legitimate signatures are not confirmed.

In response, Nebraskans for Medical Cannabis criticized the state’s policies, stating that it is alarming that the state is attempting to silence Nebraskans based on largely speculative legal issues.

The legal filing accuses petition circulators of fraud or other misconduct in 72 of Nebraska’s 93 counties. Hilgers’ office claims that three notaries acted as both circulator and notary on an unspecified number of petitions, while six others notarized documents without witnessing the signatures in person, as required.

A total of eight notaries have been accused of misconduct. If the signatures collected by these individuals are disqualified, it could potentially void about 49,000 signatures on both the legalization and regulatory petitions.

Additionally, four circulators are accused of fraudulent activities, though the filing doesn’t specify the exact nature of the fraud. In total, about 656 signatures on each petition are at risk of being disqualified due to alleged fraud.

Hilgers argued that the burden of proving the signatures’ validity should fall on the petition sponsors, stating that when fraud or misconduct is discovered, any associated signatures lose their presumption of validity. His office is asking the court to take an even tougher stance than a 1919 state Supreme Court ruling that nullified signatures tied to fraudulent circulators during a referendum on women’s suffrage.

The investigation points to more than 30 people suspected of wrongdoing, including high rates of signature rejections. One sponsor involved is Crista Eggers, campaign manager for Nebraska Families 4 Medical Marijuana. As of now, no additional charges have been filed against any other circulators or notaries connected to the cannabis petitions.

This marks the third attempt by Nebraskans for Medical Cannabis to get the measure on the ballot. The organization’s first effort in 2020 was blocked by the state Supreme Court, and in 2022, the group failed to gather enough signatures. While several measures will appear on the Nov. 5 ballot this year, Evnen and Hilgers are focusing their scrutiny solely on the medical cannabis initiatives.

These efforts to block the passage of laws legalizing medical or recreational marijuana aren’t new. Companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) have seen similar issues arise in different markets, but the reform movement scores gains sooner or later.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Clarifying Congress’ Intent on THC Could Help in Reforming Marijuana Laws

Back in 2018 when Congress passed the current farm bill that legalized hemp, Congress seemed to have been under the belief that hemp was for making rope rather than intoxicating products. However, the current debate around hemp is almost solely rotating around intoxicants.

It has become abundantly clear that the law passed in 2018, in a way, spawned the current proliferation of derivatives, including THC products. There is a heated debate, with people on either side making arguments in support of their positions. For example, the hemp industry wants the current law to remain as it is, leaving makers of hemp-derived THC intoxicants to operate in the current legal gray area. They claim that the phrasing “all derivatives” opened the gate to THC products from hemp and the status quo should remain.

Opponents argue that THC products from hemp aren’t under the purview of any regulatory framework and that is untenable, since any product intended for the market should be regulated in one way or the other.

One factor has become clear as efforts are made to close the so-called “hemp loophole”: the congressional committees that are responsible for formulating hemp policy aren’t the right entities to make laws giving the U.S. Food and Drug Administration (FDA) power over any product. The committees simply oversee agriculture. This explains why, up until now, no regulations have been passed guiding the FDA on how CBD should make its way onto the market or into different consumable products.

Even if the upcoming farm bill was used to provide guidance on THC derived from hemp, it creates more challenges than it solves. For example, would states that have permitted hemp intoxicants renew their laws at least once every five years? Secondly, the Drug Enforcement Administration specifically categorizes synthetic THC as a schedule 1 substance, and not even the reclassification of marijuana would change this classification.

It is becoming increasingly clear that whether THC is derived from marijuana or hemp, it needs to be regulated by a single legal regime. This could mean that manufacturers of hemp-sourced THC products have to adhere to new or existing laws on product testing, advertising, marketing and more. Insisting that the product continue to exist within a “loophole” is counterproductive for the industry in more ways than one. For example, institutional investors are likely to be unwilling to fund such ventures since the segment is open to all manner of legal challenge.

Now may be the time to establish the right regulatory framework for hemp, so that the growth of the industry isn’t left to chance because this risks not only public health but also the very economic interests of those currently engaged in hemp derivative manufacturing.

Regulatory clarity on all forms of THC would help the hemp and cannabis industry, including companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), to be more certain about the conditions under which they should expect to operate and make their future plans.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Home Depot Internal Memo Indicates Company Will Stop Employee Marijuana Tests

One of the largest employers in the United States, Home Depot, is rewriting its rules regarding employee drug testing. A recent document states that the corporation is discontinuing pre-employment substance testing for the majority of its personnel and will no longer include marijuana in its substance-screening panels.

The revised policies will go into effect on Sept. 1, 2024, as stated in a message from human resources distributed this week. According to the memo, cannabis will no longer be tested on drug panels in the U.S., which includes tests carried out following workplace mishaps or in circumstances where there is a plausible suspicion of impairment.

The memo also clarifies that only external candidates with conditional offers for positions such as corporate security and asset protection will be subject to pre-employment substance testing. The changes, however, have no bearing on federal Department of Transportation employees, who are still subject to the current testing procedures.

News of the policy shift first surfaced on Reddit in the r/HomeDepot forum. A user posted that they had been informed of the new protocol during a morning meeting. The user mentioned that as of Sept. 1, 2024, cannabis would no longer be included in drug tests, even in cases of reasonable suspicion. Additionally, the user noted that drug testing for lift equipment operators would also be discontinued.

The Reddit post quickly garnered attention, with several other users claiming to work at Home Depot confirming that they had heard similar updates at their workplaces.

If the changes are implemented, Home Depot will be among the largest private corporations to do away with cannabis testing for staff members. The corporation has more than 400,000 employees spread across some 2,000 outlets in the United States.

The move by Home Depot is not entirely unprecedented. Amazon, another corporate giant, announced in 2021 that it would no longer test a large number of its workers for cannabis use. Additionally, several states have also enacted laws that restrict or prohibit employee substance testing for cannabis. For instance, new employee protections were implemented in Washington State and California this year.

Employers in California are no longer permitted to inquire about a candidate’s prior cannabis use and cannot penalize employees for lawful use of cannabis outside of work. Meanwhile, Washington State’s law protects employees against discrimination for using legal cannabis before being hired, but it does not shield current employees from facing disciplinary action or termination due to their usage of the drug.

Major cannabis companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are probably happy that the vestiges of prohibition in the form of pre-employment drug tests are being peeled away by one company after another. With time, the substance could eventually gain the same status as other substances, such as alcohol.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Farm Bill, Cannabis Rescheduling Trigger Intense Industry Lobbying

Cannabis corporations are spending more than ever to sway lawmakers in Congress, as evidenced by a federal lobbying report analysis. This expenditure is motivated by the first real steps toward federal marijuana legalization in a generation as well as threats from competitors using hemp as a raw material.

Marijuana companies spent nearly $4 million in the first and second quarters of 2024, a significant increase from $2.4 million in 2023. This surge in spending mirrors a similar uptick in late 2022, when cannabis banking reform seemed imminent during a congressional session. The current rise, however, is more significant because it takes into account the larger range of legislation that is being considered, such as the farm bill and the Biden administration’s efforts to reschedule cannabis, which may lessen the restrictions imposed by Section 280E.

Charlie Panfil, a prominent lobbyist with the Daschle Group, a public policy agency based in Washington, DC, says there is increasing awareness that marijuana reform is becoming a more bipartisan subject.

While the spending data show the resources being used to influence politicians at the federal level, the data does not fully convey the scope of the endeavors. Significant time and effort is also devoted to cannabis-related problems by powerful political players with strong interests in marijuana, such as the beer behemoth Anheuser-Busch and the tobacco company Altria Client Services. However, lobbying reports do not completely reflect this.

A wide range of entities have been interacting with Congress on cannabis-related issues during the past year. These include large insurance corporations, financial unions, and lobbyists for state and municipal government agencies.

Despite these efforts, the impact remains uncertain. It is unlikely that the current Congress will adjourn with any major advancements toward a new farm bill or banking reform. This may indicate that the legal loophole allowing the online sale of intoxicating hemp-derived goods in the majority of the United States will remain in place.

Furthermore, the U.S. Department of Justice’s rescheduling procedure is largely outside the purview of Congress, and Section 280E will stay in force until the process is completed, a procedure that is unlikely to be influenced by lobbyists.

Advocacy groups and individual marijuana multistate operators (MSOs) in Washington, DC, continue to have a substantial amount of spending power. For instance, Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), an MSO based in Chicago, has invested $1.24 million this year for internal lobbyists and to keep the services of significant government relations companies such as Brownstein Hyatt Farber Schreck, which also represents credit unions in congressional lobbying on marijuana banking. Compared to the $250,000 the company spent in the first half of 2023, this is a significant rise.

Curaleaf Holdings also spends $290,000 every quarter on lobbying. Of that amount, $80,000 goes to Brownstein Hyatt Farber Schreck, $140,000 goes to its in-house lobbyist and $70,000 goes to Cozen O’Connor Public Strategies, an advisory company.

In some instances, the spending by cannabis companies rivals that of major companies. For instance, the $80,000 that Cresco Labs paid to Brownstein Hyatt Farber Schreck is the same amount that McDonald’s paid to Brownstein Hyatt Farber Schreck during the same period.

The additional challenges that cannabis companies encounter as a result of federal cannabis regulation are also highlighted by the companies’ higher spending. This might encourage legislators to delay resolving these difficulties because cannabis companies will have to keep paying for lobbying services for a longer period if these concerns remain, according to some observers.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Ohio Dispensaries See Long Lines as Recreational Marijuana Sales Begin

Last week, Ohioans flocked to dispensaries for the highly anticipated launch of recreational cannabis sales. Almost 100 medical cannabis dispensaries were permitted to sell recreational marijuana to adults after obtaining operational certificates from the state’s marijuana control division.

In Cincinnati, Jeffrey Reide was so excited about the historic day that he camped out in his car to ensure he would be the first in line at a local dispensary. “I’m thrilled; this has been a long time coming,” Reide said, reflecting the sentiment of many others eagerly awaiting this moment. Similar scenes were observed in Youngstown and Columbus, where dispensaries reported long lines of excited consumers anxious to make their first legal purchases.

One of the early birds in Columbus was Bloom Medicinals, located at 1361 Georgesville Road, which opened its doors around eight in the morning. The dispensary welcomed about 20 customers, all keen to be among the first to purchase cannabis without needing a prescription.

The store, originally a medicinal dispensary, set up a separate line to accommodate its regular customers who still rely on marijuana for medical purposes. Customers waited in orderly lines at the security station to have their identification examined to make sure they were authorized to purchase marijuana.

In terms of pricing, most cannabis flower products were approximately $40 for 2.83 grams, roughly equivalent to one-tenth of an ounce. The pricing range for edibles was wider, varying from $17 to $100 based on the product’s size and nature. Gavin McKenney, general manager of Bloom Medicinals, pointed out that consumers used to buying marijuana in Michigan would find that Ohio’s costs are a little higher for the time being.

While 98 locations were given the all-clear to begin selling, it was unclear how many were up and running from the outset.

Ohio voters approved the legalization of recreational marijuana last November, allowing adults 21 years of age and older to buy, possess and cultivate limited quantities of marijuana for personal use. However, the start of sales was postponed while the state established a regulated framework for transactions and finalized other regulations.

Under the new regulations, adults can purchase and hold up to 2.5 ounces of marijuana. Additionally, individuals are permitted to cultivate up to 6 plants at home, with a household limit of 12 plants. A 10% tax applies to legal sales; this revenue will be used to pay for job programs and social-equity initiatives within the cannabis sector, as well as to support addiction treatment, municipalities that have dispensaries and administrative expenditures.

The entire marijuana industry, including players such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), will be happy that the sales launch in Ohio went without a major glitch and will hope that more retail outlets open quickly so that residents can have easy access to the products they need.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — California Moves to Crackdown on Hemp Intoxicants

It has become clear in recent years that obtaining a cannabis license is both expensive and complicated. As a result, many people have found it easier to sell intoxicating products, such as hemp THC beverages. However, this trend may be shifting, especially in California.

Hemp THC beverages are drinks that contain hemp-derived delta-9 THC. You might be wondering how this is possible given the federal law that restricts THC content to 0.3%. Interestingly, these beverages can still be intoxicating without exceeding this limit. For instance, a drink containing 5 to 10 milligrams of hemp-derived THC can be intoxicating while still maintaining a THC concentration below 0.3%, depending on its weight.

California Governor Gavin Newsom issued an order in April for the Alcoholic Beverage Control (ABC) and the Public Health Department (CDPH) to ensure hemp products sold in the state adhere to the law. The initiative, titled California Takes Action to Protect Youth from Illegal Hemp Products, emphasizes the need to prevent mislabeled and misleading products from reaching the market, particularly to safeguard children’s health.

The directive highlighted concerns about highly intoxicating hemp beverages appearing in retail stores, which could easily end up in the hands of minors. Hemp products, distinct from those in the legal market, must adhere to stringent consumer safety regulations, including precise labeling requirements. Failure to comply with these regulations is illegal and can lead to license revocation.

Following the directive, both ABC and CDPH issued general warnings to entities about potentially illegal hemp products.

Last week, CDPH specifically warned consumers against drinking hemp-infused sodas under the Mary Jones branding, alleging that the drinks contained isolate of delta-9 THC. As per the CDPH, state law prohibits the inclusion of THC isolate as a component in hemp products.

This warning, which indicates that CDPH views goods containing THC isolates could be dangerous, might have a big impact on the California hemp THC beverage market. The future actions of CDPH remain uncertain, especially regarding companies that produce hemp THC drinks without using THC isolates. State law grants CDPH and other regulators substantial authority to target companies selling “misbranded” or “adulterated” products. These terms can be interpreted broadly, potentially encompassing any product with intoxicating cannabinoids.

Under California law, “THC” broadly consists of:

tetrahydrocannabinolic acid
tetrahydrocannabinol of any kind regardless of how they are derives (the CDPH may exclude certain isomers from this definition)
any other cannabis compound, except CBD, that CDPH determines to be intoxicating.

This definition indicates that CDPH may examine any psychoactive cannabinoid, not just isolate of delta-9 THC. Additionally, there are federal considerations to keep in mind. Recent proposed amendments to Farm Bill 2024 aim to limit intoxicating cannabis compounds. While the amendments do not specify a restrictive milligram cap for hemp THC beverages, they do exclude products with “quantifiable levels” of THC or other intoxicating cannabis compounds from the definition of hemp. The exact meaning of “quantifiable levels” will be determined by federal regulators, which could result in regulations that effectively ban intoxicating hemp THC drinks.

The actions taken by California regulators to crackdown on hemp intoxicants could help to clarify the boundaries between the THC products from licensed companies in various jurisdictions, such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), and products synthesized from hemp.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Reports Indicate DEA Didn’t Support Marijuana Reclassification

In a secluded section of the U.S. Drug Enforcement Administration (DEA) headquarters known as the 12th-floor “bubble,” director Anne Milgram called a special “marijuana meeting” in March 2024 where she made an unusual request: no one was allowed to take notes. During the meeting, she informed her top deputies that the Biden administration was about to reschedule cannabis as a less-harmful substance, a significant move toward federal legalization that the agency has historically opposed.

Moreover, Milgram disclosed that this reclassification would be handled by the U. S. Department of Justice, not the DEA, and the final decision would be signed by Merrick Garland, the attorney general.

Milgram did not provide a reason for this unprecedented decision, and neither she nor the agency has done so subsequently. However, the plan unfolded exactly as she described, marking the most significant change in U.S. drug policy in half a century, without the DEA’s support.

The DEA has not yet determined the proper schedule for cannabis, according to a statement tucked on page 13 of Garland’s 92-page decision, which was released last Thursday. According to the order, cannabis would be moved from Schedule I, which is more restricted and contains narcotics such as LSD and heroin, to Schedule III, which is less restrictive and includes anabolic steroids and ketamine.

Internal documents show that the agency sent a memo to the DOJ in January, requesting more scientific data to determine if cannabis has approved medical use, a crucial factor for reclassification. However, DOJ attorneys overruled the DEA’s criteria, considering them too restrictive.

Several DEA officers, both past and present, indicated that political considerations could be driving this action. Rather than giving the DEA more time to carry out additional research, they think the DOJ is rushing the recategorization of marijuana to aid Biden in winning support from voters for his reelection campaign.

The DOJ’s engagement in the rescheduling process, in the opinion of retired DEA agent Derek Maltz, puts politics ahead of public safety. He underlined that such choices must be supported by scientific analysis.

Tim Shea, a former administrator of the DEA, echoed this statement, stating that Milgram’s absence from the signature shows her support for the DEA personnel. He voiced concern that the agency’s position had been overridden by political interference, which he said demoralized DEA staff.

The White House didn’t immediately respond, but it has said in the past that Biden is devoted to his pledge made during the campaign that no citizen should be imprisoned for marijuana use. DOJ attorneys supported Garland’s order, pointing out that it resulted from different perspectives held by the HHS and the DEA. Last year, HHS recommended rescheduling cannabis, considering it less harmful than drugs such as heroin and cocaine, and recognizing its effectiveness in treating conditions such as pain and anorexia.

Despite this recommendation, the DEA disagreed, citing the increasing potency of cannabis and the rise in emergency room visits due to its use. The DEA’s concerns were cited multiple times in Garland’s order. The DOJ, however, emphasized that it is legally bound to follow HHS’s medical and scientific determinations on drug classification.

The internal conflict highlights the ongoing debate over the risks of marijuana, despite 38 and 24 states legalizing it for medical and recreational use, respectively. Public support for legalization is also at an all-time high, with 70% of American adults in favor, according to a Gallup poll. Critics argue that the DEA’s stance is outdated and not aligned with public opinion.

The reclassification process, initiated by Biden’s 2022 order for a review, is expected to be lengthy. The DEA will take public comments on the proposal before an administrative judge reviews it and a final rule is published. While federal marijuana prosecutions are rare, its classification as a Schedule III drug would still subject it to regulation.

Milgram has not publicly discussed her position on cannabis. Known for her data-driven and progressive approach, she has historically viewed the legalization debate as less critical compared to the fentanyl crisis. Her recent brief announcement to DEA employees stated only that the agency would comply with posting the notice and attachments on its website, leaving her personal views on the matter unclear.

This revelation that the DEA wasn’t party to the recent announcement to reclassify marijuana federally may be of little consequence to the marijuana industry and its major actors such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) as the resulting policy change will require the compliance of all federal agencies.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — US Cannabis Companies Could Soon Access Bankruptcy Protection

U.S. cannabis businesses undergoing distress often face hurdles in seeking bankruptcy protection, a common challenge in an industry prone to business downturns. However, there’s a glimmer of hope on the horizon with potential federal rescheduling of cannabis and shifting perspectives evident in recent bankruptcy cases.

Duane Morris Law firm associate, Ryan Spengler, expressed cautious optimism, noting that advancements in court rulings coupled with potential rescheduling may pave the way for new bankruptcy avenues for U.S. marijuana businesses. He stated that even before federal rescheduling, if bankruptcy courts begin to show leniency towards marijuana-related companies, it could signal a positive trend for the industry.

Meanwhile, distressed marijuana enterprises are exploring out-of-court restructuring and state court receiverships as alternatives to filing for federal bankruptcy. Some are even turning to Canadian insolvency rules, where applicable.

Federal bankruptcy laws in the United States mandate that bankruptcy plans must be proposed in good faith and in compliance with all applicable regulations. Since cannabis remains illegal under federal law, even state-regulated cannabis companies are excluded from federal bankruptcy protections.

Although rescheduling marijuana might seem like a solution, Spengler points out that it wouldn’t address the federal barrier to bankruptcy. He explains that regardless of whether marijuana is classified as Schedule I or III, bankruptcy courts would still view it as a federal violation.

New court rulings, nevertheless, provide some hope. A possible change in perspective is indicated by the fact that certain courts have started to permit the division of assets connected to cannabis for the advantage of debtors and creditors.

For instance, a 2023 ruling by a California bankruptcy court set a precedent by allowing the sale of stock in a Canadian marijuana company as part of a bankruptcy plan. Similarly, another case in 2023 saw approval from a bankruptcy court indicating the potential for more innovative approaches in marijuana bankruptcy cases.

Rescheduling marijuana could present fresh prospects for bankrupt cannabis companies, according to Kevin McLaughlin, a partner at Centri Business Consulting. He anticipates that eliminating 280E taxation, which is associated with Schedule III classification, could make cannabis businesses more attractive for restructuring. Despite the limitations in bankruptcy options, McLaughlin notes that cannabis companies still have alternatives such as out-of-court restructuring and receivership.

In the meantime, as regulated cannabis companies await changes in bankruptcy laws, income derived from the marijuana industry also poses challenges in personal bankruptcy cases.

Recent court decisions indicate a gradual shift away from a strict stance against marijuana-involved debtors seeking bankruptcy relief. This shift offers a glimmer of hope for individuals working in the industry who may seek bankruptcy protection in the future.

Any positive reforms to the existing federal marijuana policies are likely to be a welcome development to industry actors such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) given how much the current prohibitionist environment has hamstrung their operations and growth.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Maine Sounds Alarm on Illicit Marijuana Linked to Chinese Gangs

Maine is becoming the new hub for the illegal cannabis trade, with numerous unlicensed cultivation houses scattered across the state, according to a recent investigation conducted by CBS News. This trend mirrors a broader phenomenon unfolding countrywide, with illegal cannabis farms sprouting up in various states, such as Colorado, Oklahoma and California, as highlighted by the DEA’s former head of operations, Raymond Donovan.

Donovan attributes Maine’s strategic suitability for marijuana cultivation to its discreet geographical location and proximity to prominent distribution hubs such as New York and Boston.

A notable instance occurred in December when law enforcement authorities, after a comprehensive six-week probe, conducted a raid in Machias, uncovering a sizable facility housing more than 100 pounds of packaged cannabis and 2,600 plants. Chief of police Keith Mercier described it as one of the largest indoor cannabis cultivation operations he had encountered in his extensive career.

The operation involved a collaborative effort, with Machias police receiving assistance from various agencies including Homeland Security, the U.S. Federal Bureau of Investigation (FBI) and the U.S. Drug Enforcement Administration (DEA), among others. Since June 2023, Maine officials have executed search warrants at 34 properties associated with illegal cannabis activities, with ongoing investigations.

Surprisingly, investigations into the spread of illegal cultivation operations in Maine’s remote areas have pointed to involvement from Chinese organized crime networks. According to Donovan, these networks, which operate internationally, are linked to some of the largest black market cannabis trafficking operations. The issue prompted 50 U.S. legislators to address Merrick Garland, the U.S. attorney general, seeking clarification on China’s involvement in illegal cannabis activities across the country.

Maine Wire editor Steve Robinson has been monitoring the electricity usage of suspected illicit marijuana growers, a key indicator of illicit activity. He observed that such operations consume exorbitant amounts of electricity, necessitating significant upgrades to electrical infrastructure, which are often challenging to obtain.

Mercier acknowledged Robinson’s contributions, mentioning the utilization of his insights as a training tool prior to executing search warrants. The excessive electricity consumption, coupled with other red flags such as shuttered windows, strong odors and suspicious vehicular traffic, led law enforcement to the Machias operation, resulting in the arrest of three individuals on charges of unlawful cultivation.

Donovan highlighted a concerning aspect of the workforce involved in cannabis grow operations, revealing that some Chinese nationals are labor trafficking victims. Exploited under the guise of legitimate employment, these individuals are coerced into overseeing the cultivation process under duress, working under deplorable conditions for minimal compensation.

Further, he noted that the criminal groups are also often involved in more sinister drug trades, including the distribution of fentanyl. The authorities traced the connection between Chinese organized crime and illegal cannabis growers through the fentanyl distribution chain, observing that profits from fentanyl sales often circulate back to Chinese money brokers in Queens and Brooklyn, who are also involved in cannabis trafficking.

Despite marijuana’s legalization in several states, including Maine, its federal illegality persists. The thriving illicit market stems from the disparity between supply and demand, with regulations unable to meet consumer needs. Donovan expressed concern that lenient prosecution could embolden organized crime syndicates to target sparsely populated states such as Maine, exploiting lax oversight to expand their illicit operations.

Licensed companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) also have to contend with the marijuana black market in the different markets in which they have operations. Decisively addressing this challenge will go a long way in allowing the legitimate companies in this industry to thrive.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com